Related Experiment Video
Updated: Aug 4, 2026

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
Published on: October 15, 2013
Inhibition of HIV infection by the cytokine midkine
C Callebaut1, S Nisole, J P Briand
1Unité de Virologie et Immunologie Cellulaire, URA 1930 CNRS, Institut Pasteur, 28 rue du Dr. Roux, 75724 Paris Cedex 15, France.
Abstract:
The growth factor midkine (MK) has been reported to bind heparan sulfate and nucleolin, two components of the cell surface implicated in the attachment of HIV-1 particles. Here we show that synthetic and recombinant preparations of MK inhibit in a dose-dependent manner infection of cells by T-lymphocyte- and macrophage-tropic HIV-1 isolates. The binding of labeled MK to cells is prevented by excess unlabeled MK or by the anti-HIV pseudopeptide HB-19 that blocks HIV entry by forming a stable complex with the cell-surface-expressed nucleolin. MK mRNA is systematically expressed in adult peripheral blood lymphocytes from healthy donors, while its expression becomes markedly but transiently increased upon in vitro treatment of lymphocytes with IL-2 or IFN-gamma and activation of T-lymphocytes by PHA or antibodies specific to CD3/CD28. In MK-producing lymphocytes, MK is detectable at the cell surface where it colocalizes with the surface-expressed nucleolin. Finally, by using MK-producing CD4(+) and CD4(-) cell clones we show that HIV infection in cell cultures could be inhibited in both an autocrine and a paracrine manner. The potent and distinct anti-HIV action of MK along with its enhanced expression in lymphocytes by various physiological stimuli suggests that MK is a cytokine that could be implicated in HIV-induced pathogenesis.
Insights
The growth factor midkine (MK) inhibits HIV-1 infection by binding to cell surface components. This cytokine’s expression increases with immune stimulation, suggesting a role in HIV pathogenesis.
Area of Science:
- Immunology
- Virology
- Molecular Biology
Background:
- Midkine (MK) binds heparan sulfate and nucleolin, cell surface components involved in HIV-1 attachment.
- HIV-1 entry into cells is a critical step in viral infection.
Purpose of the Study:
- To investigate the potential of midkine (MK) as an inhibitor of HIV-1 infection.
- To explore the role of MK in lymphocyte responses to HIV-1.
Main Methods:
- Inhibition assays using synthetic and recombinant MK against HIV-1 isolates.
- Cell surface binding studies with labeled MK and anti-HIV pseudopeptide HB-19.
- Analysis of MK mRNA expression in lymphocytes stimulated with cytokines and mitogens.
- Colocalization studies of MK and nucleolin on lymphocyte cell surfaces.
- Assessment of HIV infection inhibition in MK-producing CD4(+) and CD4(-) cell clones.
Main Results:
- MK demonstrated dose-dependent inhibition of T-lymphocyte- and macrophage-tropic HIV-1 infection.
- MK binding to cells was blocked by excess MK or HB-19, indicating a shared binding mechanism with nucleolin.
- MK mRNA expression was constitutive in lymphocytes and increased upon stimulation with IL-2, IFN-gamma, PHA, or anti-CD3/CD28 antibodies.
- MK was detected at the cell surface of lymphocytes, colocalizing with nucleolin.
- MK inhibited HIV infection in both autocrine and paracrine manners in cell cultures.
Conclusions:
- Midkine (MK) possesses potent anti-HIV-1 activity by interfering with viral entry.
- Enhanced MK expression in lymphocytes upon immune activation suggests a regulatory role in HIV infection.
- MK is a cytokine implicated in the pathogenesis of HIV infection.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly

